Journal article

Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study

Ian T Meredith, John Ormiston, Robert Whitbourn, I Patrick Kay, David Muller, Jeffrey J Popma, Donald E Cutlip, Peter J Fitzgerald

AMERICAN JOURNAL OF CARDIOLOGY | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | Published : 2007

Abstract

The Endeavor zotarolimus-eluting stent (ZES; Medtronic Vascular, Santa Rosa, CA) has been found to provide event-free clinical outcomes to 2 years for the treatment of symptomatic CAD by suppressing neointimal proliferation of the target lesion. The clinical outcomes of patients treated with the Endeavor ZES were evaluated at 4 years after implantation. One hundred consecutive patients with symptomatic ischemic heart disease due to de novo stenotic lesions of native coronary arteries were treated with the Endeavor ZES at 8 centers according to a standardized procedure. At 4 years, 3 patients were lost to follow-up analysis. The incidence of major adverse cardiac events (MACE; defined as deat..

View full abstract